KR101980164B1 - 재조합 ｆｖｉｉｉ의 생산에서 진핵 세포의 생산성을 증가시키는 방법 - Google Patents

재조합 ｆｖｉｉｉ의 생산에서 진핵 세포의 생산성을 증가시키는 방법 Download PDF

Info

Publication number
KR101980164B1
KR101980164B1 KR1020137029808A KR20137029808A KR101980164B1 KR 101980164 B1 KR101980164 B1 KR 101980164B1 KR 1020137029808 A KR1020137029808 A KR 1020137029808A KR 20137029808 A KR20137029808 A KR 20137029808A KR 101980164 B1 KR101980164 B1 KR 101980164B1
Authority
KR
South Korea
Prior art keywords
cell
cell suspension
cells
rfviii
productivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137029808A
Other languages
English (en)
Korean (ko)
Other versions
KR20140021009A (ko
Inventor
페테르 아이자바
이레네 아게르크비스트
Original Assignee
옥타파마 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45470754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101980164(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 옥타파마 아게 filed Critical 옥타파마 아게
Publication of KR20140021009A publication Critical patent/KR20140021009A/ko
Application granted granted Critical
Publication of KR101980164B1 publication Critical patent/KR101980164B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/42—Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020137029808A 2011-05-13 2012-05-14 재조합 ｆｖｉｉｉ의 생산에서 진핵 세포의 생산성을 증가시키는 방법 Expired - Fee Related KR101980164B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11166071 2011-05-13
EP11166071.8 2011-05-13
US201161489406P 2011-05-24 2011-05-24
US61/489,406 2011-05-24
PCT/EP2012/058899 WO2012156356A1 (en) 2011-05-13 2012-05-14 A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii

Publications (2)

Publication Number Publication Date
KR20140021009A KR20140021009A (ko) 2014-02-19
KR101980164B1 true KR101980164B1 (ko) 2019-05-20

Family

ID=45470754

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137029808A Expired - Fee Related KR101980164B1 (ko) 2011-05-13 2012-05-14 재조합 ｆｖｉｉｉ의 생산에서 진핵 세포의 생산성을 증가시키는 방법

Country Status (13)

Country Link
US (1) US9115381B2 (enExample)
EP (3) EP3626737B1 (enExample)
JP (1) JP6178786B2 (enExample)
KR (1) KR101980164B1 (enExample)
CN (1) CN103517919B (enExample)
AU (1) AU2012257736B2 (enExample)
BR (1) BR112013028006A2 (enExample)
CA (1) CA2835053C (enExample)
DK (1) DK3626737T3 (enExample)
ES (1) ES2970057T3 (enExample)
IL (1) IL229058A (enExample)
RU (1) RU2600886C2 (enExample)
WO (1) WO2012156356A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6591609B2 (en) 1997-07-15 2003-07-15 New Power Concepts Llc Regenerator for a Stirling Engine
ES2909630T3 (es) 2014-06-04 2022-05-09 Amgen Inc Métodos de recolección en cultivos de células de mamífero
CN107287265B (zh) * 2016-03-31 2018-09-14 正大天晴药业集团南京顺欣制药有限公司 一种制备重组人凝血因子ⅷ的方法
CN112469821B (zh) * 2018-07-26 2021-12-14 正大天晴药业集团股份有限公司 一种制备重组人凝血因子ⅷ的方法
WO2023242238A1 (en) * 2022-06-15 2023-12-21 UCB Biopharma SRL Cell culture processes
CN120005720B (zh) * 2025-04-21 2025-08-08 深圳市茵冠生物科技有限公司 一种人工智能的细胞培养监测方法及系统

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
NZ516400A (en) * 1999-07-13 2004-02-27 Biovitrum Ab Stable factor VIII compositions
EP1460131A3 (en) 2000-03-22 2005-06-01 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
CN104593277A (zh) * 2004-03-05 2015-05-06 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
JP2006296423A (ja) * 2005-03-24 2006-11-02 Hitachi Ltd 培養槽の制御装置及び培養装置
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
JP2008534559A (ja) * 2005-04-01 2008-08-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 血液凝固ｆｖｉｉｉ類似体
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
PT2634243T (pt) 2006-07-14 2017-12-18 Patheon Holdings I B V Método para melhorar a cultura de células
CN101490239A (zh) * 2006-07-14 2009-07-22 帝斯曼知识产权资产管理有限公司 改进的细胞培养方法
WO2009090787A1 (ja) * 2008-01-15 2009-07-23 Toray Industries, Inc. 生理活性ペプチドまたはタンパク質製造方法、および組換え動物細胞
SI2300497T1 (sl) * 2008-06-24 2013-02-28 Octapharma Ag Postopek za äťiĺˇäťenje koagulacijskega faktorja viii
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
DE102008049120A1 (de) 2008-09-26 2010-04-01 Bayer Technology Services Gmbh Verfahren zur Reduzierung von Ablagerungen bei der Kultivierung von Organismen
EP2216395A1 (en) 2009-02-09 2010-08-11 Lonza Biologics plc. Bioreactor for the cultivation of mammalian cells
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Barrett TA et al, Biotechnology and Bioengineering, 2010, 105(2):260-275
Zhang, HU et al., Current Pharmaceutical Biotechnology, 2010, 11(1):103-112

Also Published As

Publication number Publication date
CN103517919A (zh) 2014-01-15
US20140051123A1 (en) 2014-02-20
US9115381B2 (en) 2015-08-25
AU2012257736B2 (en) 2015-12-10
RU2600886C2 (ru) 2016-10-27
EP3626737B1 (en) 2023-11-29
KR20140021009A (ko) 2014-02-19
EP4353743A2 (en) 2024-04-17
ES2970057T3 (es) 2024-05-24
IL229058A (en) 2017-03-30
EP4353743A3 (en) 2024-07-17
WO2012156356A1 (en) 2012-11-22
CN103517919B (zh) 2016-11-16
JP2014513545A (ja) 2014-06-05
JP6178786B2 (ja) 2017-08-09
IL229058A0 (en) 2013-12-31
BR112013028006A2 (pt) 2016-09-06
EP2707387B1 (en) 2019-12-25
RU2013155382A (ru) 2015-06-20
DK3626737T3 (da) 2024-02-05
EP3626737A1 (en) 2020-03-25
EP2707387A1 (en) 2014-03-19
CA2835053C (en) 2020-07-07
CA2835053A1 (en) 2012-11-22
AU2012257736A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
KR101980164B1 (ko) 재조합 ｆｖｉｉｉ의 생산에서 진핵 세포의 생산성을 증가시키는 방법
US20240247218A1 (en) Large scale pei-mediated plasmid transfection
Birch et al. Suspension culture of mammalian cells
Reuveny Microcarrier culture systems
EA022219B1 (ru) Способ получения полипептида или вируса, представляющих интерес, в непрерывной клеточной культуре
Han et al. Cultivation of recombinant Chinese hamster ovary cells grown as suspended aggregates in stirred vessels
EA016451B1 (ru) Способ суспензионного культивирования клеток
US8440800B2 (en) Compositions for reducing cell adhesion to bubbles
US11781102B2 (en) Large-scale PEI-mediated plasmid transfection
JP2023503849A (ja) 接種物を生産するためのプロセスおよびシステム
Nie et al. The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process
Hong et al. Development of an alternating tangential flow (ATF) perfusion‐based transient gene expression (TGE) bioprocess for universal influenza vaccine
Chalmers The challenges of hydrodynamic forces on cells used in cell manufacturing and therapy
ES2777173T3 (es) Un procedimiento para aumentar la productividad de células eucarióticas en la producción de FVIII recombinante
Ahmed Application of hydrocyclone for cell separation in mammalian cell perfusion cultures
Heathman et al. The Scale‐up of Human Mesenchymal Stem Cell Expansion and Recovery
US20210214702A1 (en) Process for production of recombinant tnk-tpa by packed-bed perfusion system
ARATHOON JOHN R. BIRCH

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220515

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220515